AI Article Synopsis
- Acinetobacter is becoming a major concern in global healthcare due to its ability to develop pan-resistance, complicating patient treatment and increasing mortality rates.
- A recent case from Pakistan involved a 22-year-old patient whose severe symptoms eventually revealed pan-resistant Acinetobacter after initial treatments failed.
- The report emphasizes the need for improved diagnostic methods, effective antibiotic combinations, and innovative treatment strategies to better manage infections caused by this resistant pathogen.
Article Abstract
Acinetobacter has emerged as a highly important organism in global healthcare, owing to its propensity to develop pan-resistance. This resistant pathogen poses a significant challenge to healthcare professionals because it not only restricts patient care through ineffective treatment modalities but also leads to high mortality and morbidity rates. The case of a 22-year-old young man reporting to the Emergency department (ER) of Pakistan Institute of Medical Sciences (PIMS), Islamabad, on 6th June, 2023 is presented. He complained of fever accompanied with seizures which gave a suspicion of autoimmune encephalitis or viral haemorrhagic fever. Despite initial therapeutic interventions, the patient's condition worsened, prompting further investigations. Culture and sensitivity testing of tracheal secretions revealed pan-resistance, and subsequent treatment with a combination of antibiotics including Tigecycline and Colistin, yielded a favourable response. The aim for reporting this case, is to highlight the challenges inherent in diagnosing and managing patients with pan-resistant Acinetobacter, as antimicrobial resistance continues to evolve. Furthermore, research endeavours should focus on identifying safe and effective antibiotic combinations, exploring novel treatment approaches, and improving patient outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.47391/JPMA.10688 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fecal microbiota transplantation in severe pneumonia: a case report on overcoming pan-drug resistant infection.
Front Med (Lausanne)
December 2024
Department of Respiratory and Critical Care Medicine, Fuzong Clinical Medical College of Fujian Medical University, Dongfang Hospital of Xiamen University, The 900th Hospital of Joint Logistics Support Force, Fuzhou, China.
Objective: To evaluate the therapeutic potential of fecal microbiota transplantation (FMT) in treating severe pneumonia patients with concurrent pan-drug resistant infection.
Methods: A case report of a 95-year-old female patient with severe pneumonia, complicated by pan-resistant bacterial infections, is presented. The patient was diagnosed with severe pneumonia caused by COVID-19, along with co-infections of , , , , ESBL-producing pan-drug resistant and pan-resistant .
Isolation and characterization of Acinetobacter phage vAbaIN10 active against carbapenem Resistant Acinetobacter baumannii (CRAB) isolates from healthcare-associated infections in Dakar, Senegal.
J Glob Antimicrob Resist
December 2024
Pôle de Microbiologie, Institut Pasteur de Dakar, Sénégal; Faculté de Médecine, Pharmacie et Odontostomatologie, Université Cheikh Anta Diop, Dakar, Sénégal.
Article Synopsis
- Acinetobacter baumannii, especially the carbapenem-resistant strains (CRAB), is a critical pathogen linked to antimicrobial resistance (AMR) and is prioritized by the WHO.
- Phage therapy is being explored as a potential treatment for CRAB infections due to increasing resistance to conventional antibiotics.
- A newly isolated lytic phage, vAbaIN10, exhibits effective lytic activity against CRAB in various conditions and shows promise in advancing treatment options for multidrug-resistant infections.
New emerging materials with potential antibacterial activities.
Appl Microbiol Biotechnol
November 2024
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, The Medical Campus of Tanta University, Elgeish Street, Tanta, 31111, Egypt.
The increasing prevalence of multidrug-resistant pathogens is a critical public health issue, necessitating the development of alternative antibacterial agents. Examples of these pathogens are methicillin-resistant Staphylococcus aureus (MRSA) and the emergence of "pan-resistant" Gram-negative strains, such as Pseudomonas aeruginosa and Acinetobacter baumannii, which occurred more recently. This review examines various emerging materials with significant antibacterial activities.
View Article and Find Full Text PDFTreating a patient with pan-resistant Acinetobacter: a case study.
J Pak Med Assoc
October 2024
5th Year MBBS Student, Federal Medical College, Pakistan Institute of Medical Sciences, Islamabad, Pakistan.
Article Synopsis
- Acinetobacter is becoming a major concern in global healthcare due to its ability to develop pan-resistance, complicating patient treatment and increasing mortality rates.
- A recent case from Pakistan involved a 22-year-old patient whose severe symptoms eventually revealed pan-resistant Acinetobacter after initial treatments failed.
- The report emphasizes the need for improved diagnostic methods, effective antibiotic combinations, and innovative treatment strategies to better manage infections caused by this resistant pathogen.
Polymyxins retain activity and efficacy against "resistant" strains when tested in physiological conditions.
Antimicrob Agents Chemother
October 2024
Department of Molecular Microbiology and Immunology, Keck School of Medicine of USC, Los Angeles, California, USA.
The emergence of plasmid-mediated resistance threatens the efficacy of polymyxins as the last line of defense against pan-drug-resistant infections. However, we have found that using Mueller-Hinton II (MHII), the standard minimum inhibitory concentration (MIC) medium, results in MIC data that are disconnected from treatment outcomes. We found that culturing putative colistin-resistant clinical isolates, as defined by MICs of >2 mg/L in standard MHII testing conditions, in bicarbonate-containing media reduced MICs to the susceptible range by preventing colistin resistance-conferring lipopolysaccharide modifications from occurring.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!